Lallemand’s probiotic claim approved claim in Canada for supporting adults with IBS

Lallemand Health Solutions (Montreal, CA) reports that its probiotic strain L. paracasei HA-196 has been approved for a new health claim in Canada. The health claim recognizes the strain’s ability to support healthy bowel habits in adults with irritable bowel syndrome (IBS) at a daily dose of 10 billion colony-forming units (CFU).

A 2020 randomized, double-blind, placebo-controlled study¹ in 251 North American Adults showed that after eight weeks of supplementation, L. paracasei HA-196 reduced frequency of bowel movements in those with IBS-D (diarrhea), increased bowl frequency in those with IBS-C (constipation), and supported quality of life in IBS subjects, including supporting emotional well-being and social functioning.

The company reports that IBS affects approximately 10%-15% of the global population, according to estimates from the International Foundation for Functional Gastrointestinal Disorders.

Reference

1. Lewis ED et al. “Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of irritable bowel syndrome (IBS): A randomized, placebo-controlled study.” Nutrients, vol. 12, no. 4 (April 21, 2020): 1159